Scientific Presentations, Abstracts, and Posters - Bimekizumab Scientific Presentations, Abstracts, and Posters - Bimekizumab
CONTENT PROVIDED FOR SHAREHOLDERS, INVESTORS, AND OTHER CAPITAL MARKET PARTICIPANTS ONLY The following documents are specifically for shareholders, investors, and other capital market participants. This webpage is not intended for other members of the general public. If you are not a shareholder, investor, or other capital market participant, please return to UCB's homepage. Bimekizumab Presentations, Abstracts, Posters EULAR 2023 Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2 Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2 Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies AAD Meeting 2022 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial Bimekizumab efficacy and safety through two years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial EULAR 2022 Bimekizumab in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from BE MOBILE 2, a Phase 3, Multicentre, Randomised, Placebo-Controlled Study Maintenance of Response to Bimekizumab Over 3 Years of Treatment in Patients with Active Ankylosing Spondylitis: Post Hoc Analyses from the BE AGILE Study and its Open-Label Extension Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from BE MOBILE 1, a Phase 3, Multicentre, Randomised, Placebo-Controlled Study Bimekizumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from BE COMPLETE, a Phase 3, Multicentre, Randomised, Placebo-Controlled Study Bimekizumab in bDMARD-Naïve Patients with Psoriatic Arthritis: 24-Week Efficacy & Safety from BE OPTIMAL, a Phase 3, Multicentre, Randomised, Placebo-Controlled, Active Reference Study EADV 2022 Bimekizumab versus secukinumab in plaque psoriasis: Cumulative clinical and health‑related quality of life benefit through 2 years of the BE RADIANT phase 3b trial and open‑label extension Bimekizumab in patients with active non-radiographic axial spondyloarthritis and active ankylosing spondylitis: 24-week efficacy and safety from the BE MOBILE phase 3 studies Efficacy and safety of bimekizumab in bDMARD-naïve patients with psoriatic arthritis: 24-week results from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study Efficacy and safety of bimekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: 16-week results from BE COMPLETE, a phase 3, randomised, double-blind placebo-controlled study Bimekizumab efficacy through 96 weeks in patients with moderate to severe plaque psoriasis: Patient-reported outcomes from the BE RADIANT phase 3b trial Bimekizumab versus secukinumab in plaque psoriasis: Cumulative clinical and health‑related quality of life benefit through 2 years of the BE RADIANT phase 3b trial and open‑label extension Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial Bimekizumab efficacy over two years in patients with moderate to severe plaque psoriasis with scalp and nail involvement who switched from adalimumab, ustekinumab, or secukinumab: Results from the BE SURE, BE VIVID, BE BRIGHT, and BE RADIANT phase 3/3b trials Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Pooled results through two years from the BE SURE and BE RADIANT phase 3 trials Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials A network meta-analysis of cumulative clinical benefit of anti-IL biologics for the treatment of moderate to severe psoriasis over 48–52 weeks Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials ACR Meeting 2022 Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study Bimekizumab Improves Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Achieving Increasingly Stringent Clinical Disease Control Criteria is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
